Application of paeoniflorin in preparation of medicine for preventing or treating acute graft versus host disease
Paeoniflorin addresses the challenges of preventing and treating aGVHD by regulating donor hematopoietic stem cell metabolism and gut microbiota, thereby inhibiting T cell activation and achieving low-toxicity, high-efficiency prevention and treatment effects.
CN121059623APending Publication Date: 2025-12-05THE SECOND AFFILIATED HOSPITAL ARMY MEDICAL UNIV
0 Cites 0 Cited by
Patent Information
- Application Number
- CN202511132739.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-08-13
- Publication Date
- 2025-12-05
AI Technical Summary
Technical Problem
Existing technologies for the prevention and treatment of acute graft-versus-host disease (aGVHD) suffer from problems such as significant side effects, unstable efficacy, and narrow applicability, and there is a lack of effective drug solutions.
Method used
Using paeoniflorin as a monomeric compound, this study aims to regulate the metabolic pathways of donor hematopoietic stem cells, inhibit T cell activation and the release of inflammatory factors, restore gut microbiota balance, and reduce immune-mediated organ damage.
Benefits of technology
It can effectively prevent or treat aGVHD, reduce the score, improve survival, reduce liver and kidney toxicity and infection risk, promote hematopoietic recovery, restore immune homeostasis, and protect the intestinal barrier.
✦ Generated by Eureka AI based on patent content.
Abstract
The invention relates to the technical field of biological medicine, and discloses application of paeoniflorin in preparation of medicine for preventing or treating acute graft versus host disease. The invention can promote hematopoietic recovery to regulate immune homeostasis. The donor hematopoietic stem cells are mobilized, glycometabolism, fatty acid metabolism and amino acid metabolism pathways of the hematopoietic stem cells are activated in a targeted manner, the activity of the transplanted hematopoietic stem cells is enhanced, and hematopoietic reconstruction is accelerated. The application disclosed by the invention can play a role in preventing or treating aGVHD by inhibiting amplification and activation of donor T cells, inhibiting release of inflammatory cytokines / chemotactic factors, improving the level of anti-inflammatory cytokines, relieving intestinal injury, balancing intestinal flora and other mechanisms.
Need to check novelty before this filing date? Find Prior Art